Article
TAPO in first-line osimertinib therapy and continuation of osimertinib.
Thoracic cancer - 1 Feb 2023
Mimura Chihiro, Kaneshiro Kazumi, Fujimoto Shodai, Dokuni Ryota, Iwamoto Natsuhiko, Matsumura Kanoko, Hatakeyama Yukihisa, Kono Yuko, Tachihara Motoko
Abstract excerpt
BACKGROUND: Osimertinib is associated with a relatively high frequency of drug-induced interstitial lung disease (D-ILD), and transient asymptomatic pulmonary opacities (TAPO) have been reported to occur during osimertinib administration. The frequency of TAPO during first-line treatment and the pros and cons of osimertinib continuation is unknown. METHODS: This was a multicenter, retrospective study. The purpose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.